{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:55:01Z","timestamp":1788432901307,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1124\/jpet.113.209478","type":"journal-article","created":{"date-parts":[[2013,11,14]],"date-time":"2013-11-14T05:41:23Z","timestamp":1384407683000},"page":"217-226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["A Double Blind, within Subject Comparison of Spontaneous Opioid Withdrawal from Buprenorphine versus Morphine"],"prefix":"10.1016","volume":"348","author":[{"given":"D. Andrew","family":"Tompkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam Z.","family":"Mintzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia M.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Strain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.113.209478_bib1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0376-8716(00)00141-1","article-title":"Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans","volume":"61","author":"Amass","year":"2001","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.113.209478_bib2","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2000"},{"key":"10.1124\/jpet.113.209478_bib3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jsat.2004.05.002","article-title":"Opioid detoxification using high doses of buprenorphine in 24 hours: a randomized, double blind, controlled clinical trial","volume":"27","author":"Assadi","year":"2004","journal-title":"J Subst Abuse Treat"},{"key":"10.1124\/jpet.113.209478_bib4","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1389-9457(00)00065-4","article-title":"Validation of the Insomnia Severity Index as an outcome measure for insomnia research","volume":"2","author":"Bastien","year":"2001","journal-title":"Sleep Med"},{"key":"10.1124\/jpet.113.209478_bib5","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0196-9781(00)00252-7","article-title":"Agonistic effects of the opioid buprenorphine on the nociceptin\/OFQ receptor","volume":"21","author":"Bloms-Funke","year":"2000","journal-title":"Peptides"},{"key":"10.1124\/jpet.113.209478_bib6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/clpt.1980.219","article-title":"Buprenorphine kinetics","volume":"28","author":"Bullingham","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.113.209478_bib7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","article-title":"The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research","volume":"28","author":"Buysse","year":"1989","journal-title":"Psychiatry Res"},{"key":"10.1124\/jpet.113.209478_bib8","unstructured":"Center for Substance Abuse Treatment (2004) Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series 40. Substance Abuse and Mental Health Services Administration, Rockville, MD."},{"key":"10.1124\/jpet.113.209478_bib9","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/bjp.2008.100","article-title":"Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction","volume":"154","author":"Christie","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.113.209478_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.drugalcdep.2005.08.005","article-title":"Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine","volume":"82","author":"Compton","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.113.209478_bib11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00213-006-0571-4","article-title":"Effects associated with double-blind omission of buprenorphine\/naloxone over a 98-h period","volume":"189","author":"Correia","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.113.209478_bib12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1476-5381.1977.tb07532.x","article-title":"Agonist and antagonist properties of buprenorphine, a new antinociceptive agent","volume":"60","author":"Cowan","year":"1977","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.113.209478_bib13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0014-2999(81)90163-1","article-title":"Buprenorphrine: demonstration of physical dependence liability","volume":"70","author":"Dum","year":"1981","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.113.209478_bib14","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1476-5381.1981.tb10473.x","article-title":"In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions","volume":"74","author":"Dum","year":"1981","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.113.209478_bib15","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0022-3565(25)12294-5","article-title":"Buprenorphine\u2019s physical dependence potential: antagonist-precipitated withdrawal in humans","volume":"276","author":"Eissenberg","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.113.209478_bib16","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003088-200544070-00001","article-title":"Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence","volume":"44","author":"Elkader","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/jpet.113.209478_bib17","series-title":"Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I\/P), Biometrics Research","author":"First","year":"2002"},{"key":"10.1124\/jpet.113.209478_bib18","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/clpt.1990.67","article-title":"Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal","volume":"47","author":"Fudala","year":"1990","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.113.209478_bib19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.biopsych.2006.04.043","article-title":"Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices","volume":"61","author":"Greenwald","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1124\/jpet.113.209478_bib20","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","article-title":"Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers","volume":"28","author":"Greenwald","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.113.209478_bib21","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archpsyc.1983.01790070055007","article-title":"Differential effects of diazepam and pentobarbital on mood and behavior","volume":"40","author":"Griffiths","year":"1983","journal-title":"Arch Gen Psychiatry"},{"key":"10.1124\/jpet.113.209478_bib22","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/00952998709001515","article-title":"Two new rating scales for opiate withdrawal","volume":"13","author":"Handelsman","year":"1987","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1124\/jpet.113.209478_bib23","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-15-5-829","article-title":"The morphine abstinence syndrome, its nature and treatment","volume":"15","author":"Himmelsbach","year":"1941","journal-title":"Ann Intern Med"},{"key":"10.1124\/jpet.113.209478_bib24","series-title":"Drug Addiction I","first-page":"197","article-title":"Assessment of the abuse potentiality of morphine-like drugs (methods used in man)","author":"Jasinski","year":"1977"},{"key":"10.1124\/jpet.113.209478_bib25","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archpsyc.1978.01770280111012","article-title":"Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction","volume":"35","author":"Jasinski","year":"1978","journal-title":"Arch Gen Psychiatry"},{"key":"10.1124\/jpet.113.209478_bib26","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM200011023431802","article-title":"A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence","volume":"343","author":"Johnson","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.113.209478_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0376-8716(95)01189-7","article-title":"Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing","volume":"40","author":"Johnson","year":"1995","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.113.209478_bib28","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/00004714-199006000-00002","article-title":"Dose-response evaluation of the amnestic effects of triazolam and pentobarbital in normal subjects","volume":"10","author":"Kirk","year":"1990","journal-title":"J Clin Psychopharmacol"},{"key":"10.1124\/jpet.113.209478_bib29","first-page":"69","article-title":"Current pharmacotherapies for opioid dependence","volume":"26","author":"Kosten","year":"1990","journal-title":"Psychopharmacol Bull"},{"key":"10.1124\/jpet.113.209478_bib30","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/jat\/20.6.369","article-title":"Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine","volume":"20","author":"Kuhlman","year":"1996","journal-title":"J Anal Toxicol"},{"key":"10.1124\/jpet.113.209478_bib31","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1360-0443.1998.93454910.x","article-title":"Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine","volume":"93","author":"Kuhlman","year":"1998","journal-title":"Addiction"},{"key":"10.1124\/jpet.113.209478_bib32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0014-2999(99)00460-4","article-title":"Differential binding properties of oripavines at cloned \u03bc- and \u03b4-opioid receptors","volume":"378","author":"Lee","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.113.209478_bib33","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2174\/1381612043453027","article-title":"The orvinols and related opioids\u2014high affinity ligands with diverse efficacy profiles","volume":"10","author":"Lewis","year":"2004","journal-title":"Curr Pharm Des"},{"key":"10.1124\/jpet.113.209478_bib34","doi-asserted-by":"crossref","first-page":"10331","DOI":"10.1523\/JNEUROSCI.23-32-10331.2003","article-title":"Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors","volume":"23","author":"Lutfy","year":"2003","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.113.209478_bib35","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0022-3565(25)30536-7","article-title":"The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog","volume":"197","author":"Martin","year":"1976","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.113.209478_bib36","doi-asserted-by":"crossref","unstructured":"Mattick RP, Kimber J, Breen C, Davoli M (2008) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev (2):CD002207.pub3.","DOI":"10.1002\/14651858.CD002207.pub3"},{"key":"10.1124\/jpet.113.209478_bib37","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3758\/BF03203313","article-title":"An automated version of the digit symbol substitution test (DSST)","volume":"14","author":"McLeod","year":"1982","journal-title":"Behav Res Meth Instrum"},{"key":"10.1124\/jpet.113.209478_bib38","series-title":"EITS Manual for the Profile of Mood States","author":"McNair","year":"1971"},{"key":"10.1124\/jpet.113.209478_bib39","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1126\/science.7352279","article-title":"Buprenorphine suppresses heroin use by heroin addicts","volume":"207","author":"Mello","year":"1980","journal-title":"Science"},{"key":"10.1124\/jpet.113.209478_bib40","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00008877-199711000-00014","article-title":"Triazolam and zolpidem: a comparison of their psychomotor, cognitive, and subjective effects in healthy volunteers","volume":"8","author":"Mintzer","year":"1997","journal-title":"Behav Pharmacol"},{"key":"10.1124\/jpet.113.209478_bib41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/0269881103017001689","article-title":"Triazolam-amphetamine interaction: dissociation of effects on memory versus arousal","volume":"17","author":"Mintzer","year":"2003","journal-title":"J Psychopharmacol"},{"key":"10.1124\/jpet.113.209478_bib42","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.drugalcdep.2011.03.024","article-title":"Gender differences in pharmacokinetics of maintenance dosed buprenorphine","volume":"118","author":"Moody","year":"2011","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.113.209478_bib43","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/00008877-200211000-00005","article-title":"Delta opioid antagonist effects of buprenorphine in rhesus monkeys","volume":"13","author":"Negus","year":"2002","journal-title":"Behav Pharmacol"},{"key":"10.1124\/jpet.113.209478_bib44","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1360-0443.1994.tb00898.x","article-title":"Naloxone-induced withdrawal in patients with buprenorphine dependence","volume":"89","author":"Nigam","year":"1994","journal-title":"Addiction"},{"key":"10.1124\/jpet.113.209478_bib45","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/0024-3205(90)90220-L","article-title":"Buprenorphine-induced pupillary effects in human volunteers","volume":"47","author":"Pickworth","year":"1990","journal-title":"Life Sci"},{"key":"10.1124\/jpet.113.209478_bib46","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0022-3565(25)10212-7","article-title":"Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers","volume":"264","author":"Preston","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.113.209478_bib47","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2466\/pms.1958.8.3.271","article-title":"The validity of the trail-making test as an indicator of organic brain damage","volume":"8","author":"Reitan","year":"1958","journal-title":"Percept Mot Skills"},{"key":"10.1124\/jpet.113.209478_bib48","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0376-8716(99)00012-5","article-title":"Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet","volume":"56","author":"Schuh","year":"1999","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.113.209478_bib49","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s002130000637","article-title":"Effects of buprenorphine\/naloxone in opioid-dependent humans","volume":"154","author":"Stoller","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.113.209478_bib50","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.drugalcdep.2003.11.008","article-title":"Relative bioavailability of different buprenorphine formulations under chronic dosing conditions","volume":"74","author":"Strain","year":"2004","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.113.209478_bib51","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0022-3565(25)24449-4","article-title":"Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone","volume":"272","author":"Strain","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.113.209478_bib52","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s002130050066","article-title":"Effects of buprenorphine versus buprenorphine\/naloxone tablets in non-dependent opioid abusers","volume":"148","author":"Strain","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.113.209478_bib53","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.drugalcdep.2009.07.001","article-title":"Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument","volume":"105","author":"Tompkins","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.113.209478_bib54","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0022-3565(25)09651-X","article-title":"Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure","volume":"273","author":"Walker","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.113.209478_bib55","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","article-title":"The clinical opiate withdrawal scale (COWS)","volume":"35","author":"Wesson","year":"2003","journal-title":"J Psychoactive Drugs"},{"key":"10.1124\/jpet.113.209478_bib56","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1521-0391.2012.00259.x","article-title":"Course and treatment of buprenorphine\/naloxone withdrawal: an analysis of case reports","volume":"21","author":"Westermeyer","year":"2012","journal-title":"Am J Addict"},{"key":"10.1124\/jpet.113.209478_bib57","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1185\/03007995.2012.678938","article-title":"Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain","volume":"28","author":"Wolff","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1124\/jpet.113.209478_bib58","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1124\/jpet.105.100859","article-title":"Buprenorphine activates mu and opioid receptor like-1 receptors simultaneously, but the analgesic effect is mainly mediated by mu receptor activation in the rat formalin test","volume":"318","author":"Yamamoto","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.113.209478_bib59","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.drugalcdep.2008.06.016","article-title":"Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence","volume":"99","author":"Ziedonis","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.113.209478_bib60","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0893-133X(00)00110-X","article-title":"Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study","volume":"23","author":"Zubieta","year":"2000","journal-title":"Neuropsychopharmacology"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524272050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524272050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.113.209478","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T20:10:01Z","timestamp":1739995801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524272050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0022356524272050"],"URL":"https:\/\/doi.org\/10.1124\/jpet.113.209478","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Double Blind, within Subject Comparison of Spontaneous Opioid Withdrawal from Buprenorphine versus Morphine","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.113.209478","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}